Answers are grounded in this paper and cite their sources.
A perspective of our work on the development of practical metal‐mediated carbon‐carbon and carbon‐heteroatom bond forming processes within a modern drug portfolio is presented. The case studies selected from our laboratories highlight the synthetic challenges and opportunities presented by pharmaceutically relevant scaffolds. In many cases, the target structures challenged available synthetic methods and inspired the invention of enabling technology to accelerate drug development. Additionally, considerations for running metal‐mediated processes on large scale are discussed.
No takes yet. Share an insight, caveat, or question.
Borths et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: